Uniqure (QURE) Shares Up -0.3%

Shares of Uniqure NV (NASDAQ:QURE) shot up 0.3% on Thursday . The company traded as high as $29.74 and last traded at $28.91. 148,552 shares changed hands during trading, a decline of 61% from the average session volume of 380,774 shares. The stock had previously closed at $29.01.

Several brokerages have recently commented on QURE. Zacks Investment Research downgraded Uniqure from a “hold” rating to a “sell” rating in a research note on Saturday, February 24th. HC Wainwright set a $35.00 target price on Uniqure and gave the company a “buy” rating in a research note on Tuesday, February 20th. BidaskClub upgraded Uniqure from a “hold” rating to a “buy” rating in a research note on Saturday, March 24th. ValuEngine upgraded Uniqure from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. Finally, Janney Montgomery Scott restated a “buy” rating and issued a $30.00 target price on shares of Uniqure in a research note on Tuesday, March 20th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $21.38.

The company has a quick ratio of 8.46, a current ratio of 8.46 and a debt-to-equity ratio of 0.22. The company has a market cap of $856.42, a P/E ratio of -9.88 and a beta of 0.18.



Uniqure (NASDAQ:QURE) last issued its earnings results on Wednesday, March 14th. The biotechnology company reported ($0.91) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by ($0.23). The firm had revenue of $2.58 million during the quarter, compared to analyst estimates of $2.83 million. Uniqure had a negative net margin of 604.72% and a negative return on equity of 174.25%. equities research analysts forecast that Uniqure NV will post -3.21 EPS for the current year.

In related news, CEO Matthew C. Kapusta sold 39,169 shares of the firm’s stock in a transaction dated Thursday, March 15th. The shares were sold at an average price of $21.72, for a total value of $850,750.68. Following the transaction, the chief executive officer now owns 439,764 shares of the company’s stock, valued at approximately $9,551,674.08. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Deventer Sander Van sold 5,985 shares of the firm’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $18.53, for a total transaction of $110,902.05. The disclosure for this sale can be found here. In the last ninety days, insiders sold 48,032 shares of company stock worth $1,014,982. 0.73% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC bought a new position in Uniqure in the 4th quarter valued at about $119,000. Ellington Management Group LLC bought a new position in Uniqure in the 4th quarter valued at about $237,000. Goldman Sachs Group Inc. bought a new position in Uniqure in the 4th quarter valued at about $373,000. Virtus Fund Advisers LLC bought a new position in Uniqure in the 4th quarter valued at about $389,000. Finally, Two Sigma Advisers LP bought a new position in Uniqure in the 4th quarter valued at about $476,000. 42.76% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This article was posted by Dakota Financial News and is the property of of Dakota Financial News. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at https://dakotafinancialnews.com/2018/04/12/uniqure-qure-shares-up-0-3.html.

About Uniqure

uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company's principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease.

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply